MultiPlan Corporation
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
It is alleged in this complaint that MultiPlan made misleading and/or false statements and/or failed to disclose that: (1) MultiPlan was losing tens of millions of dollars in revenues and sales to Naviguard, a competitor that had been created by one of MultiPlan’s largest customers, UnitedHealthcare, which threatening up to 35% of MultiPlan’s sales and 80% of its levered cash flows by 2022; (2) revenues and sales declines in the quarters leading up to the Merger were not due to “idiosyncratic” customer behaviors as had been represented by MultiPlan, but rather due to increased competition and a fundamental deterioration in demand for MultiPlan’s services, as payers developed competing services seeking alternatives to eliminating excessive healthcare costs; (3) MultiPlan was facing significant pricing pressures for its services and had been forced to materially reduce its take rate in the period leading up to the Merger by insurers, who had expressed a dissatisfaction with the quality and price of MultiPlan’s balanced billing practices and services, which caused MultiPlan to cut its take rate by up to half in some cases; (4) MultiPlan was set to continue to suffer from earnings and revenue declines, increased competition and deteriorating pricing dynamics in the period following the Merger, as a result; (5) MultiPlan was forced to seek continued revenue growth and to improve its competitive positioning by way of costly acquisitions, which included the purchase of the healthcare technology company HST for $140 million at a premium price from a former MultiPlan executive only one month after the Merger, consequently; and (6) as such, investors had grossly overpaid for the acquisition of MultiPlan in the Merger, while MultiPlan’s business was worth far less than had been represented to investors.
